Response rate | Systemic chemotherapy+ cetuksimab, number (%) | Systemic chemotherapy+ bevacizumab, number (%) |
---|---|---|
Complete response | 7 (13) | 6 (17) |
Partial response | 18 (34) | 8 (23) |
Stable disease | 21 (40) | 19 (54) |
Progression of disease | 7 (13) | 2 (6) |
Response rate | Codon 12 mutations, number (%) | Codon 13 mutations, number (%) |
---|---|---|
Complete response | 6 (12) | 2 (12) |
Partial response | 5 (11) | 6 (35) |
Stable disease | 23 (49) | 7 (41) |
Progression of disease | 13 (28) | 2 (12) |
Patient’s characteristics | Number (%) |
---|---|
Medium age (years) | 62 |
Gender | |
female | 59 (38) |
male | 95 (62) |
WHO performance status | |
0 | 36 (23) |
1 | 109 (71) |
2 | 9 (6) |
Tumour location | |
colon | 112 (73) |
rectum | 42 (27) |
Primary metastatic | 89 (58) |
Liver metastases | 68 (44) |
Disease characteristics | Number (%) |
---|---|
pT4 of primary tumour | 35 (23) |
Affected regional lymph nodes (N) | |
N0 (no affected regional lymph nodes) | |
N1 (1 to 3 affected regional lymph nodes) | 34 (22) |
N2 (more than 3 affected regional lymph nodes) | 61 (40) 59 (38) |
Vascular invasion | 22 (14) |
Perineal invasion | 25 (16) |
Lymphangiosis | 27 (17) |
Grade of differentiation | |
G1 (well) | 10 (6) |
G2 (medium) | 131 (85) |
G3 (poorly) | 13 (8) |
non-mutated (wild-type) | 89 (58) |
mutated | 65 (42) |
codon 12 | 48 (73) |
codon 13 | 17 (27) |
non-mutated (wild-type) | 150 (97) |
mutated | 4 (3) |
Grade 1 n (%) | Grade 2 n (%) | Grade 3 n (%) | Grade 4 n (%) | |
---|---|---|---|---|
Haematological | ||||
leukopenia | 42 (27) | 8 (5) | 1 (1) | |
neutropenia | 42 (27) | 8 (5) | 1+1 | |
thrombocytopenia | 33 (21) | 11 (7) | (1+1)* | |
anaemia | 88 (57) | 10 (6) | ||
Non-haematological | ||||
alopecia | 62 (40) | 21 (14) | / | / |
fatigue | 93 (60) | 11 (7) | 0 | / |
nausea | 40 (26) | 10 (6) | 0 | / |
vomiting | 14 (9) | 9 (6) | 0 | 0 |
diarrhea | 23 (15) | 29 (19) | 2 (2) | 1 (1) |
stomatitis | 4 (3) | 2 (2) | 0 | 0 |
hand-foot syndrome | 17 (11) | 6 (4) | 0 | / |
peripheral sensory neuropathy | 32 (21) | 8 (5) | 0 | 0 |
hepatic toxicity | 17 (11) | 3 (2) | 0 | 0 |
renal toxicity | 0 | 0 | 1 (1) | 0 |
acneiform rash | 14 (9) | 38 (25) | 0 | 0 |
hypermagnesemia | 6 (4) | 0 | 3 (2) | 0 |
allergic reaction to cetuximab | 3 (2) | 1 (1) | 0 | 0 |
allergic reactions to oxaliplatin | 1 (1) | 0 | 0 | 0 |
arterial hypertension | 3 (2) | 9 (6) | 0 | / |
proteinuria | 20 (13) | 18 (12) | 0 | 0 |
bleeding | 6 (4) | 0 | 1 (1) | |
thromboembolic events | 0 | 7 (5) | 0 | 0 |
wound complications | 0 | 0 | 0 | / |
perforation | 0 | 0 | 0 | 0 |
arthralgia | 17 (11) | 2 (2) | 0 | 0 |
bladder infection | / | 3 (2) | 0 | 0 |